Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis

Glucagon-like peptide-1 (GLP-1) agonists are a class of drugs used for the treatment of type 2 diabetes mellitus. GLP-1 is released in response to meal intake; these classes of drugs enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic effects following their release into the circulation from the gut. Psoriasis is a chronic skin condition affecting approximately 2% of the Western population. It is considered to be an autoimmune disease that involves the Th1 pathway and is associated with metabolic syndrome and its components, such as obesity, diabetes, and hypertension. We have reviewed reports in the literature that indicate a beneficial anti-inflammatory effect of GLP-1 in patients with diabetes or who have insulin resistance and psoriasis.

[1]  E. Maverakis,et al.  Diagnosis and classification of psoriasis. , 2014, Autoimmunity reviews.

[2]  L. Skov,et al.  Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide , 2014, Acta Diabetologica.

[3]  C. Sweeney,et al.  Glucagon‐like peptide‐1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  D. O'Shea,et al.  Liraglutide in combination with acitretin for severe recalcitrant psoriasis , 2013, The British journal of dermatology.

[5]  J. Holst,et al.  Increased expression of glucagon‐like peptide‐1 receptors in psoriasis plaques , 2013, Experimental dermatology.

[6]  V. Preumont,et al.  Improvement of psoriasis during exenatide treatment in a patient with diabetes. , 2012, Diabetes & metabolism.

[7]  L. Skov,et al.  Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism? , 2011, Medical hypotheses.

[8]  K. Hashimoto,et al.  Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Psoriasis , 2011, Dermatology.

[9]  D. Drucker,et al.  Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology , 2011, Diabetologia.

[10]  D. Doherty,et al.  Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis , 2011, Diabetologia.